Serum Institute and Oxford License a Next-Generation Malaria Vaccine

The Serum Institute of India and the University of Oxford's Jenner Institute signed a licensing pact on 29 April 2026 for R78C, a next-generation malaria vaccine designed to deliver stronger and longer-lasting protection than the single-antigen shots now in the field. The agreement moves the candidate toward clinical evaluation and, critically, large-scale manufacture.

A multi-stage design

R78C is a multi-stage vaccine targeting two Plasmodium falciparum blood-stage antigens, RIPR and CyPRA. That is the technical departure. R21/Matrix-M and its predecessor RTS,S target the parasite's pre-erythrocytic (sporozoite) stage, the brief window after a mosquito bite and before the parasite multiplies in red blood cells. By instead hitting blood-stage antigens, and two of them rather than one, R78C aims to attack the parasite at the phase responsible for clinical disease and to make immune escape harder. Combining antigens is a standard strategy for broadening and durability, where single-antigen vaccines have shown waning efficacy.

The candidate is currently pre-clinical, so this is an early-stage bet; the licensing deal accelerates the path to human trials rather than marking an approval. It builds directly on the Serum-Oxford partnership behind R21/Matrix-M, which Serum manufactures at 100 million doses per year and supplies through a Gavi-UNICEF agreement struck in November 2025.

India's manufacturing edge

The strategic point is supply, not just science. Malaria's burden falls overwhelmingly on low- and middle-income countries, where ability to pay is low and volume requirements are enormous. Serum's edge is precisely there: the scale and cost structure to produce hundreds of millions of equitable, affordable doses, the same capability that made R21 deployable across Africa.

The pattern recurs across India's vaccine pipeline. Pune-based Gennova Biopharma is advancing a self-amplifying mRNA (saRNA) Nipah vaccine with CEPI backing of up to $13.38 million; saRNA platforms replicate inside cells, allowing protective immunity from far smaller doses. For investors, the thesis is consistent: India's value in global vaccines is increasingly about marrying frontier antigen science to LMIC-scale, low-cost manufacturing.